Granules India Limited (NSE:GRANULES)
476.00
-2.70 (-0.56%)
Mar 12, 2025, 3:29 PM IST
Granules India Revenue
Granules India had revenue of 11.38B INR in the quarter ending December 31, 2024, a decrease of -1.55%. This brings the company's revenue in the last twelve months to 44.60B, down -1.46% year-over-year. In the fiscal year ending March 31, 2024, Granules India had annual revenue of 45.06B, down -0.12%.
Revenue (ttm)
44.60B
Revenue Growth
-1.46%
P/S Ratio
n/a
Revenue / Employee
10.99M
Employees
4,057
Market Cap
115.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
Mar 31, 2021 | 32.38B | 6.39B | 24.59% |
Mar 31, 2020 | 25.99B | 3.19B | 14.02% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Zydus Lifesciences | 222.47B |
Apollo Hospitals Enterprise | 211.46B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Granules India News
- 7 days ago - Granules India shares drop nearly 3% amid US FDA warning letter - Business Upturn
- 12 days ago - Granules India shares drop 3.6% after receiving US FDA warning letter for Gagillapur facility - Business Upturn
- 12 days ago - Top Stocks in News Today, Friday, February 28: GE Power, Coal India, Sanofi, Granules India, RVNL, Transrail Lighting, TATA Motors and more - Business Upturn
- 12 days ago - USFDA issues warning letter to Granules’ Gagillapur unit, new product nods to take hit - The Times of India
- 13 days ago - Granules India receives US FDA warning letter for Gagillapur facility - Business Upturn
- 19 days ago - Granules India acquires Senn Chemicals to expand into peptide segment and CDMO business - Business Upturn
- 5 weeks ago - Granules India gains FDA approval for generic Vyvanse capsules - Business Upturn
- 6 weeks ago - Granules India shares fall nearly 4% on Q3 results - Business Upturn